Prices are updated after-hours

Nasdaq Denmark

Topdanmark AS

TPDKY | $4.38 13.81% 100

(0.0% 1d) (0.0% 1m) (-23.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-67.11% volume)
Earnings Calendar:
Market Cap: $ 3,942,000,000
http://www.topdanmark.com/
Sec Filling | Patents | n/a employees

(DK)

add to watch list Paper trade email alert is off

FLSMIDTH & CO. A/S

FLIDY | $4.53 19.1% 150

Manufacturing

(0.0% 1m) (0.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-50.0% volume)
Earnings Calendar:
Market Cap: $ 2,611,545,000
http://www.flsmidth.com/
Sec Filling | Patents | n/a employees

(DK)

add to watch list Paper trade email alert is off

FLSMIDTH & CO. A/S

FLIDF | $50.45 1.2K

Non-Energy Minerals

(0.0% 1m) (22.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (6.87% volume)
Earnings Calendar:
Market Cap: $ 2,908,442,500
http://www.flsmidth.com
Sec Filling | Patents | n/a employees

(DK) FLSmidth & Co. A/S engages in the manufacture and distribution of cement and equipment for cement and mineral industries. It operates through the following segments: Customer Services, Product Companies, Minerals, and Cement. The Customer Services segment consists of full suite of parts, services, and maintenance solutions. The Product Companies segment comprises of nine companies with individually integrated business models and products spanning from pumps, cyclones, feeders and sizers to heavy-duty gears and drives, weighing and dosing solutions, bagging, palletizing and dispatching equipment as well as automation systems, air pollution control systems and pneumatic conveying. The Minerals segment provides mineral processing and material handling technology and systems. The Cement segment offers technology and process solutions to the global cement industry. The company was founded by Frederik Læssøe Smidth on January 2, 1882 and is headquartered in Valby, Denmark.

add to watch list Paper trade email alert is off

GN STORE NORD A/S

GGNDF | $25.56 50.16% 260

n/a

(0.0% 1d) (-0.9% 1m) (10.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (5100.0% volume)
Earnings Calendar:
Market Cap: $ 3,857,328,995
http://www.gn.com/
Sec Filling | Patents | n/a employees

(DK)

add to watch list Paper trade email alert is off

Forward Pharma A/S

FWPAY | $300.0 33.33% 11

n/a

(0.0% 1d) (0.0% 1m) (11011.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-83.82% volume)
Earnings Calendar:
Market Cap: $ 2,127,355,500
https://www.forward-pharma.com
Sec Filling | Patents | 2020 employees

(DK) Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen's net sales of Tecfidera® or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the Opposition Proceeding, including any appeal thereto.

treatment

add to watch list Paper trade email alert is off

Forward Pharma A/S

FWP | $1.95 7.74% 7.18%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-64.55% volume)
Earnings Calendar:
Market Cap: $ 13,827,811
http://www.forward-pharma.com
Sec Filling | Patents | 5 employees

(DK) Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 1, 2005 and is headquartered in Copenhagen, Denmark.

neurological treatment

add to watch list Paper trade email alert is off

LiqTech International, Inc.

LIQT | $2.67 -2.91% -3.0% 10K

Producer Manufacturing

(0.0% 1d) (-19.0% 1m) (-21.7% 1y) (0.0% 2d) (0.0% 3d) (-3.3% 7d) (-85.67% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 15,505,598
http://www.liqtech.com
Sec Filling | Patents | 147 employees

(DK) LiqTech International, Inc. engages in the manufacture of ceramic silicon carbide filters for the gas and liquid purification. The firm specializes in ceramic membranes for liquid filtration and diesel particulate filters for the control of soot exhaust particles from diesel engines. The company was founded by Lasse Andreassen on July 1, 2004 and is headquartered in Ballerup, Denmark.

add to watch list Paper trade email alert is off

Orsted A/S / ADR

DNNGY | $18.4671 -1.5% 85K

Utilities

(0.0% 1d) (1.5% 1m) (-37.2% 1y) (0.0% 2d) (0.0% 3d) (-2.0% 7d) (-25.42% volume)
Earnings Calendar:
Market Cap: $ 2,587,739,820
https://www.orsted.com/
Sec Filling | Patents | n/a employees

(DK)

add to watch list Paper trade email alert is off

COLOPLAST A/S

CLPBY | $12.96 -1.22% 50K

Manufacturing

(0.0% 1d) (-4.6% 1m) (-6.4% 1y) (0.0% 2d) (0.0% 3d) (0.5% 7d) (7.11% volume)
Earnings Calendar:
Market Cap: $ 27,241,920,000
https://www.coloplast.dk/
Sec Filling | Patents | n/a employees

(DK)

add to watch list Paper trade email alert is off

NOVO NORDISK A S

NONOF | $122.806 0.31% 5.1K

Health Technology

(0.0% 1d) (-5.3% 1m) (-24.8% 1y) (0.0% 2d) (0.0% 3d) (0.1% 7d) (119.29% volume)
Earnings Calendar:
Market Cap: $ 421,661,962,043
http://www.novonordisk.com
Sec Filling | Patents | n/a employees

(DK) Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

hormone diabetic diabetes insulin

add to watch list Paper trade email alert is off

Orsted A/S / ADR

DOGEF | $55.87 55.36% 380

Utilities

(0.0% 1d) (3.2% 1m) (-37.0% 1y) (0.0% 2d) (0.0% 3d) (-4.4% 7d) (337.5% volume)
Earnings Calendar:
Market Cap: $ 23,486,690,940
http://www.orsted.com
Sec Filling | Patents | n/a employees

(DK) Ørsted A/S engages in the provision of renewable energy solutions. It operates through the following business segments: Wind Power, Bioenergy & Thermal Power, Distribution & Customer Solutions and Other Activities. The Wind Power segment develops, constructs, owns, and operates offshore wind farms in Denmark, the UK, Germany, the Netherlands, USA, and Taiwan. The Bioenergy & Thermal Power segment includes the generation of heat and power from combined heat and power plants in Denmark, a gas fired power plant in the Netherlands, and a Renescience plant in the UK. The Distribution & Customer Solutions segment consists of power distribution and sale of power and gas in the wholesale and retail markets in Denmark, Sweden, Germany, and the UK, as well as optimization and hedging of its overall energy portfolio. The company was founded on March 14, 2006 and is headquartered in Fredericia, Denmark.

hepatitis renewable energy construction optical

add to watch list Paper trade email alert is off

VESTAS WIND SYSTEMS A/S

VWDRY | $8.29 5.53% 290K

Manufacturing

(0.0% 1d) (-12.0% 1m) (-8.2% 1y) (0.0% 2d) (0.0% 3d) (-0.5% 7d) (-60.82% volume)
Earnings Calendar:
Market Cap: $ 25,115,398,756
https://www.vestas.com/
Sec Filling | Patents | n/a employees

(DK)

add to watch list Paper trade email alert is off

VESTAS WIND SYSTEMS A/S

VWSYF | $25.28 -10.49% 4.6K

Producer Manufacturing

(0.0% 1d) (-11.8% 1m) (-8.8% 1y) (0.0% 2d) (0.0% 3d) (-1.3% 7d) (-92.8% volume)
Earnings Calendar:
Market Cap: $ 25,529,444,333
http://www.vestas.com
Sec Filling | Patents | n/a employees

(DK) Vestas Wind Systems A/S engages in the development, manufacture, sale, and maintenance of wind power plants. It operates through the Power Solutions and Service segments. The Power Solutions segment comprises the sale of wind power plants and wind turbines. The Service segment includes the sale of service contracts, spare parts, and related activities. The company was founded by Smith Hansen and Peder Hansen in 1945 and is headquartered in Aarhus, Denmark.

add to watch list Paper trade email alert is off

GN STORE NORD A/S

GNNDY | $71.19 75.95% 300

n/a

(0.0% 1d) (-5.6% 1m) (5.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1853.0% volume)
Earnings Calendar:
Market Cap: $ 3,581,158,703
http://www.gn.com/
Sec Filling | Patents | n/a employees

(DK)

add to watch list Paper trade email alert is off

NOVOZYMES AS/FI

NVZMF | $52.71 -8.66% 1.2K

Health Technology

(0.0% 1d) (-13.4% 1m) (1.0% 1y) (0.0% 2d) (-3.3% 3d) (-5.5% 7d) (580.56% volume)
Earnings Calendar:
Market Cap: $ 21,851,196,475
http://www.novozymes.com
Sec Filling | Patents | n/a employees

(DK) Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark.

urea agricultural agriculture

add to watch list Paper trade email alert is off

GENMAB A/S

GNMSF | $290.38 3.83% 220

Health Technology

(0.0% 1d) (-3.0% 1m) (-30.1% 1y) (0.0% 2d) (0.0% 3d) (-0.3% 7d) (-49.16% volume)
Earnings Calendar:
Market Cap: $ 18,732,635,650
http://www.genmab.com
Sec Filling | Patents | n/a employees

(DK) Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

cancer antibody treatment leukemia

add to watch list Paper trade email alert is off

COLOPLAST A/S

CLPBF | $127.9125 -17.82% 720

Health Technology

(0.0% 1d) (-3.4% 1m) (-11.0% 1y) (0.0% 2d) (0.0% 3d) (1.5% 7d) (61.76% volume)
Earnings Calendar:
Market Cap: $ 26,887,207,500
http://www.coloplast.com
Sec Filling | Patents | n/a employees

(DK) Coloplast A/S develops, manufactures, and markets medical products. It operates through the following segments: Chronic Care, Interventional Urology and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Interventional Urology segment covers the sale of urological products, including disposable products. The Wound & Skin Care segment covers the sale of wound and skin care products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.

skin

add to watch list Paper trade email alert is off

NOVOZYMES AS/FI

NVZMY | $54.46 2.54% 8.2K

Manufacturing

(0.0% 1d) (-11.1% 1m) (2.5% 1y) (0.0% 2d) (0.0% 3d) (0.8% 7d) (13.28% volume)
Earnings Calendar:
Market Cap: $ 22,576,667,805
https://www.novozymes.com/
Sec Filling | Patents | n/a employees

(DK)

add to watch list Paper trade email alert is off